Full Value of Vaccines Assessment for Invasive Non-Typhoidal Salmonella Vaccines

The need for iNTS vaccines is now increasingly being recognized, but there is no iNTS vaccine available for use in humans.

Several potential iNTS candidate vaccines are being developed, including a bivalent iNTS vaccine (Typhimurium and Enteritidis) or possibly of a trivalent vaccine (Typhi/iNTS).

Such financial investments not only need public-private partnerships, but also demand economic and public health justification.

WHO and other global partners have highlighted the need to justify investments in vaccines from a multi-stakeholder perspective.

The overall objective of this project is to develop a Full Value of Vaccines Assessment (FVVA) to understand both the general and specific value of investment in an iNTS vaccine.

IVI and WHO in partnership with multiple stakeholders intend to jointly develop the Preferred Product Characteristics, R&D roadmap, FVVA encompassing a Business case and Investment case, and a clinical development plan and regulatory pathway for iNTS vaccines.

The long-term goal of this proposal is to pave the way for the development of a safe and efficacious iNTS vaccine, in-country licensure, any necessary policy recommendations from the WHO Strategic Advisory Group of Experts on Immunization, WHO prequalification, Gavi financing, UNICEF purchasing and national technical advisory group recommendations for use.